Ibrutinib Improves PFS, Not OS in High-Risk CLL
Ibrutinib does not improve overall survival in patients with treatment-naïve chronic lymphocytic leukemia at high risk of progression, a phase 3 trial suggests.
All articles by John Eckman
IT and IV Methotrexate Produce Similar CNS Outcomes in DLBCL
Rates of CNS relapse are similar in DLBCL patients who receive high-dose IV methotrexate and those who receive IT methotrexate, phase 3 data suggest.
Teclistamab-Talquetamab Combo Rivals CAR-Ts in Rel/Ref Multiple Myeloma
Combination treatment with teclistamab and talquetamab has demonstrated activity in patients with relapsed or refractory multiple myeloma.
Axi-Cel Outperforms Standard Second-Line Treatment for LBCL
Second-line treatment with axicabtagene ciloleucel can improve overall survival when compared to standard care in patients with relapsed or refractory large B-cell lymphoma.
Ponatinib Plus Chemo May Be New Standard Care in Newly Diagnosed Ph+ ALL
A phase 3 trial suggests that ponatinib is more effective than imatinib for patients with newly diagnosed Ph+ acute lymphoblastic leukemia.
All-Oral Triplet Regimen Demonstrates Activity in Acute Promyelocytic Leukemia
An all-oral triplet regimen is safe and effective in patients with newly diagnosed acute promyelocytic leukemia, a phase 2 trial suggests.
Epcoritamab Shows Promise in Large B-Cell Lymphoma
Epcoritamab elicits durable responses in patients with relapsed or refractory large B-cell lymphoma.
CARMEN Regimen Shows Promise in MYC-Rearranged Aggressive Lymphoma
The CARMEN regimen appears effective in patients with MYC-rearranged aggressive lymphoma, including those who are HIV-positive.
ASH 2022: Trials Show Promising Results in Follicular Lymphoma
Results from 4 trials presented at ASH 2022 may help inform the treatment of newly diagnosed and relapsed/refractory follicular lymphoma.
Asciminib Shows Early Promise as Frontline Therapy for CML-CP
Early results appear promising for frontline asciminib in patients with chronic phase chronic myeloid leukemia, according to researchers.
- Loading...
Loading...
Next post in ASH 2022
Loading... 
Loading...